title: Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up.
abstract: A trial of protective efficacy which compared medium-titre Edmonston-Zagreb (EZ) measles vaccine (10(4.6) p.f.u.) from the age of 4 months with the standard Schwarz (SW) measles vaccine given from the age of 9 months was started in an urban community in Guinea-Bissau in 1985. Because trials of high-titre measles vaccine have found increased mortality among female recipients, we examined whether EZ medium-titre vaccine was associated with any long-term impact on mortality, suppression of T-cells, or growth. The mortality rate ratio over 5 years of follow-up was 1.12 for EZ children compared with children in the standard group (P = 0.63). Seventy-five percent of the children still residing in the area at 5 years of age took part in an immunological and anthropometric examination. There was no difference in T-cell subsets between the two groups. There was no difference in mid-upper-arm circumference, but EZ children were significantly shorter than the children in the standard group. In conclusion, medium-titre EZ was not associated with reduced survival or persistent immunosuppression.
authors.affiliation: Epidemiology Research Unit, Statens Seruminstitut, Copenhagen, Denmark.
authors.forename: P
authors.initials: P
authors.lastname: Aaby
authors.forename: I M
authors.initials: IM
authors.lastname: Lisse
authors.forename: H
authors.initials: H
authors.lastname: Whittle
authors.forename: K
authors.initials: K
authors.lastname: Knudsen
authors.forename: J
authors.initials: J
authors.lastname: Thaarup
authors.forename: A
authors.initials: A
authors.lastname: Poulsen
authors.forename: M
authors.initials: M
authors.lastname: Sodemann
authors.forename: M
authors.initials: M
authors.lastname: Jakobsen
authors.forename: L
authors.initials: L
authors.lastname: Brink
authors.forename: U
authors.initials: U
authors.lastname: Gansted
mesh_terms: D000367:Age Factors; D001827:Body Height; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D006169:Guinea-Bissau / Q000453:epidemiology; D006801:Humans; D007108:Immune Tolerance / Q000187:drug effects*; D007115:Immunization Schedule; D007223:Infant; D007958:Leukocyte Count; D008288:Malaria / Q000097:blood / Q000453:epidemiology / Q000469:parasitology; D008297:Male; D008458:Measles Vaccine / Q000009:adverse effects* / Q000145:classification* / Q000276:immunology; D009026:Mortality; D016016:Proportional Hazards Models; D015996:Survival Rate; D016176:T-Lymphocyte Subsets
chemical_list: D008458:Measles Vaccine